Syndicate content

CellMax Life Blood Testing Platform for Early Cancer Detection Granted Six U.S. Patents Covering Entirety of Sub-$200 Test and Platform, Which Isolates Rare CTCs) from One Tube of Blood

CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced on July 25, 2018 that six U.S. patents have been granted for the compny’s biomimetic platform CMx, which detects circulating tumor cells (CTCs). The patents cover the entire detection workflow, from the capture of very rare CTCs present at fewer than five cells per billion normal cells in early-stage cancer, to the processes ensuring their intact release and identification by means of advanced imaging techniques, allowing CellMax Life to detect CTCs in up to 90 percent of samples. In addition to these six U.S. patents, there are also 16 global patents issued and several additional patents pending in the company’s growing portfolio. “In the past, finding CTCs was not possible in pre-cancer and early-stage cancer, as the cells numbered too few to accurately identify in the bloodstream,” said Shai Friedland, MD, Chief of Gastroenterology & Hepatology, VA Palo Alto Health Care System from the Stanford University School of Medicine. “The CellMax CMx platform’s ability to achieve high sensitivity for pre-cancerous colorectal lesions, while remaining cost-effective and convenient is notable. The CMx platform positions CellMax Life’s CTC test to potentially become a standard option for the 100 million Americans over the age of 45 who are eligible for colorectal cancer screening.” The CellMax CMx platform, has its origins in research conducted on biomimetic smart materials and interfaces by Professor Ying Chih Chang at Stanford University (Professor & Research Fellow, Genomics Research Center, Academia Sinica, Taiwan, Adjunct Professor Stanford University). It captures CTCs in a process that involves passing two ml of blood through a microfluidic chip with patented surface coating – a biomimetic structure that mimics the human cell surface membrane. This membrane with custom monoclonal antibody promotes collaborative binding of CTCs, prevents non-CTC cells (such as blood cells) from sticking to the chip, and retains CTCs tightly during a gentle buffer purification. Using an air-foam technique to safely release the viable CTCs to an Eppendorf tube, the eluted cells can be placed on a slide for staining and enumeration. A patented imaging technique is utilized to locate and identify the CTCs for analysis. The eluted cells can also be cultured and used in downstream molecular analysis, including next-generation sequencing of DNA and RNA and proteomics.

Results of a clinical study utilizing CellMax’s CTC Platform, presented earlier this year at ASCO GI, demonstrated that a blood-test developed using the CTC platform can detect colorectal cancer at an early stage, and even detect pre-cancer, with accuracy ranging from 84 to 88 percent by locating and identifying CTCs.
“Tumors shed CTCs into the bloodstream starting at the early stages of cancer, which cannot be detected by standard imaging techniques,” said Rui Mei, PhD, Chief Scientific Officer of CellMax Life. “Other CTC technologies pre-process the sample in order to remove vast unwanted blood cells. But at the same time, the process can also lose precious, rare CTCs. As such, other platforms are only used for advanced cancers when CTCs are present at significantly higher numbers in a blood sample. We are excited to have a solution to the problem of finding the proverbial needle in the haystack, detecting cancer in its earliest stages when it is still curable.”

CellMax Life’s CTC platform is recognized and accredited by the College of American Pathologists and is described in 40 different publications and abstracts, including the American Society for Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the American Urological Association (AUA). Recently, the platform won the MedTech Breakthrough Award for Best New Technology in Cancer Management.

CellMax Life recently launched Zenith, a U.S. clinical study with Stanford Medicine, Johns Hopkins, the University of Southern California, and the U.S. Department of Veterans Affairs Palo Alto Health Care System to further test the accuracy of its CTC platform.

CELLMAX LIFE

CellMax Life’s mission is to transform how cancer is detected and managed with globally affordable non-invasive tests for early cancer detection and monitoring. CellMax Life’s unique expertise in circulating tumor cells (CTCs) and next-generation sequencing (NGS) of DNA, as well as circulating tumor DNA (ctDNA) has enabled it to offer highly effective precision medicine solutions for healthy people, as well as patients diagnosed with cancer.

CellMax Life’s tests include CellMax-DNA Hereditary Cancer Risk Test, CellMax-CRC Colorectal Cancer Screening Test, CellMax-Prostate Cancer Test, CellMax-LBx Liquid Biopsy for immunotherapy and targeted therapy selection, and CellMax-PanCa Monitoring Test. All clinical testing is performed at CLIA- and CAP-accredited laboratories in Sunnyvale, California, and Taipei, Taiwan.

For additional information, please visit http://www.cellmaxlife.com.

[Press release]